This is in line with the hypothesis that positive PD-L1 expression in patients with EGFR-mutant NSCLC more likely represents a constitutive activation of PD-L1 signal rather than a marker of adaptive immune response. This evidence concerns the gene EGFR and non-small cell lung carcinoma.